Toronto Dominion Bank
ALNY icon

Toronto Dominion Bank’s Alnylam Pharmaceuticals ALNY Stock Holding History

Toronto Dominion Bank’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.15M Sell
18,602
-4,597
-20% -$1.56M 0.01% 784
2025
Q4 		$9.23M Buy
23,199
+1,972
+9% +$873K 0.01% 658
2025
Q3 		$9.68M Sell
21,227
-2,404
-10% -$979K 0.02% 621
2025
Q2 		$7.71M Buy
23,631
+4,246
+22% +$1.17M 0.01% 653
2025
Q1 		$5.23M Buy
19,385
+2,611
+16% +$671K 0.01% 678
2024
Q4 		$3.95M Buy
16,774
+1,308
+8% +$344K 0.01% 757
2024
Q3 		$4.25M Buy
15,466
+3,315
+27% +$863K 0.01% 640
2024
Q2 		$2.95M Sell
12,151
-835
-6% -$132K ﹤0.01% 729
2024
Q1 		$1.94M Sell
12,986
-36,161
-74% -$6.03M ﹤0.01% 786
2023
Q4 		$9.41M Sell
49,147
-6,115
-11% -$1.04M 0.01% 565
2023
Q3 		$9.79M Buy
55,262
+24,400
+79% +$4.66M 0.02% 512
2023
Q2 		$5.86M Sell
30,862
-3,317
-10% -$658K 0.01% 673
2023
Q1 		$6.84M Sell
34,179
-2,491
-7% -$524K 0.01% 604
2022
Q4 		$8.71M Buy
36,670
+9,911
+37% +$2.11M 0.01% 545
2022
Q3 		$5.35M Sell
26,759
-61
-0.2% -$11.6K 0.01% 652
2022
Q2 		$3.91M Buy
26,820
+1,207
+5% +$171K 0.01% 613
2022
Q1 		$4.18M Buy
25,613
+2,185
+9% +$333K 0.01% 629
2021
Q4 		$3.97M Buy
23,428
+8,089
+53% +$1.5M 0.01% 673
2021
Q3 		$2.9M Sell
15,339
-451
-3% -$84.6K ﹤0.01% 689
2021
Q2 		$2.68M Buy
15,790
+97
+0.6% +$14.2K ﹤0.01% 691
2021
Q1 		$2.22M Sell
15,693
-6,136
-28% -$923K ﹤0.01% 720
2020
Q4 		$2.84M Buy
21,829
+2,620
+14% +$350K 0.01% 707
2020
Q3 		$2.8M Buy
19,209
+2,074
+12% +$295K 0.01% 661
2020
Q2 		$2.54M Buy
17,135
+2,095
+14% +$282K 0.01% 700
2020
Q1 		$1.64M Sell
15,040
-4,428
-23% -$511K 0.01% 679
2019
Q4 		$2.24M Buy
19,468
+1,679
+9% +$167K ﹤0.01% 725
2019
Q3 		$1.43M Sell
17,789
-11,395
-39% -$901K ﹤0.01% 901
2019
Q2 		$1.06M Buy
29,184
+12,811
+78% +$983K ﹤0.01% 960
2019
Q1 		$1.53M Buy
16,373
+4,163
+34% +$348K ﹤0.01% 891
2018
Q4 		$890K Buy
12,210
+2,383
+24% +$183K ﹤0.01% 917
2018
Q3 		$860K Buy
9,827
+869
+10% +$87.4K ﹤0.01% 905
2018
Q2 		$882K Buy
8,958
+2,900
+48% +$288K ﹤0.01% 934
2018
Q1 		$721K Buy
6,058
+842
+16% +$109K ﹤0.01% 861
2017
Q4 		$663K Buy
+5,216
New +$655K ﹤0.01% 819
2016
Q4 		– Sell
-664
Closed -$45K – 1223
2016
Q3 		$45K Buy
664
+243
+58% +$17.1K ﹤0.01% 1039
2016
Q2 		$23K Buy
421
+3
+0.7% +$189 ﹤0.01% 1062
2016
Q1 		$26K Buy
+418
New +$27.8K ﹤0.01% 1034

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Toronto Dominion Bank's ALNY Position: Q1 2026 in Review

Toronto Dominion Bank reduced its Alnylam Pharmaceuticals (ALNY) stake by 20% in Q1 2026, selling an estimated $1.56M and leaving 18,602 shares worth $6.15M. The position accounts for 0.01% of the portfolio, ranked #784.

Toronto Dominion Bank first reported a position in ALNY in Q1 2016 and has held it in 37 quarters since. The position peaked at $9.79M in Q3 2023. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Toronto Dominion Bank held 18,602 shares of Alnylam Pharmaceuticals worth $6.15M as of Q1 2026.
  • Toronto Dominion Bank sold 4,597 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $1.56M.
  • Alnylam Pharmaceuticals made up 0.01% of Toronto Dominion Bank's portfolio in Q1 2026, its #784 holding.
  • Toronto Dominion Bank first reported a position in Alnylam Pharmaceuticals in Q1 2016 and has held it in 37 quarters since.
  • Toronto Dominion Bank's Alnylam Pharmaceuticals position peaked at $9.79M in Q3 2023.
  • 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Toronto Dominion Bank's 13F filing for Q1 2026, filed 15 May 2026.